Shirin Khambata‐Ford

<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Christos S. Karapetis, Shirin Khambata‐Ford, Derek J. Jonker et al. · New England Journal of Medicine · 2008 · 3.6K citations

Medicine, Oncology, Pharmacology +17

Expression of Epiregulin and Amphiregulin and <i>K-ras</i> Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Shirin Khambata‐Ford, Christopher R. Garrett, Neal J. Meropol et al. · Journal of Clinical Oncology · 2007 · 1.1K citations · Full text

Medicine, Genetics, Oncology +17

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

Wendy De Roock, Derek J. Jonker, Federica Di Nicolantonio et al. · JAMA · 2010 · 747 citations

Medicine, Oncology, Pharmacology +17

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

Heinz‐Josef Lenz, Eric Van Cutsem, Shirin Khambata‐Ford et al. · Journal of Clinical Oncology · 2006 · 537 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer

Shirin Khambata‐Ford, Christopher Harbison, Lowell L. Hart et al. · Journal of Clinical Oncology · 2010 · 268 citations · Full text

Medicine, Oncology, Pharmacology +17